title: [The effectiveness of concomitant radiotherapy with S-1 and nedaplatin for tongue cancer].
abstract: The development of reconstructive surgery and the use of free flaps have allowed for a larger dissection range even for advanced tongue cancer, resulting in an improvement of the prognosis. However, both the postoperative swallowing and masticatory function are still considered to have not yet reached a satisfactory level. Accordingly, our department has been administering concurrent chemoradiotherapy (CCRT) for advanced cancer to preserve the organ and the function; there are cases in which even comparatively small tumors are difficult to dissect due to the occurrence site. We have been treating these cases using CCRT as well. We herein report our results of 10 tongue cancer cases in which CCRT with S-1 and Nedaplatin (hereinafter, referred to as SN therapy) was administered in our department from April 2002 to October 2008. The complete response rate of the SN therapy was 60. 0% (6 of 10 examples). The 5-year disease-specific survival rates were 50. 0% for Stage II, 75. 0% for Stage III, and 75. 0% for Stage IV, respectively.
authors.affiliation: Dept. of Otorhinolaryngology, Showa University, Fujigaoka Hospital.
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Shimane
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Mori
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Ono
authors.forename: Aya
authors.initials: A
authors.lastname: Kaburagi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Monden
authors.forename: Ayako
authors.initials: A
authors.lastname: Furuya
authors.forename: Kiyoaki
authors.initials: K
authors.lastname: Kamakazu
authors.forename: Sei
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Sanbe
authors.forename: Harumi
authors.initials: H
authors.lastname: Suzaki
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010094:Oxonic Acid / Q000008:administration & dosage; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014062:Tongue Neoplasms / Q000401:mortality / Q000628:therapy*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D004338:Drug Combinations; D009944:Organoplatinum Compounds; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; C053989:nedaplatin